Stock AnalizAurinia Pharmaceuticals Inc. AUPH
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Aurinia Pharmaceuticals Inc. (AUPH) is a healthcare company listed in the US with a market value of about $2.1B. In the twelve months to September 30, 2026 it had revenue of $322M and net income of $314M, a net margin of 97.7%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is financial health (5/5); the weakest is track record (2/5).
Key numbers: a P/E of 6.9, a price to free cash flow of 11.9, 5-year revenue growth of 41% a year, a 5-year average ROIC of -11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 6% below the current price.
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Pays a dividend
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $322M | $283M | $235M | $176M | $134M | $46M | $50M | $318000 | $463000 | $418000 | $173000 |
| Net income | $314M | $287M | $6M | -$78M | -$108M | -$181M | -$103M | -$88M | -$53M | -$71M | -$23M |
| Free cash flow | $177M | — | — | -$33M | -$80M | -$159M | -$72M | -$64M | -$52M | -$41M | -$19M |
| EPS (diluted) | $2.29 | $2.14 | $0.04 | $-0.58 | $-0.81 | $-1.35 | $-0.77 | $-0.66 | $-0.40 | $-0.53 | $-0.17 |
| Net margin | 97.7% | 101.5% | 2.5% | -44.5% | -80.7% | -396.8% | -204.9% | -27794.0% | -11464.1% | -16935.9% | -13465.3% |
| ROIC | — | 14.1% | -0.9% | -18.8% | -21.3% | -29.3% | -25.0% | -24.1% | -32.1% | -26.3% | -55.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $18.29, 16% above the current price; targets range from $16.00 to $21.00; the consensus rating is “Buy”; expected EPS is $0.97 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Aurinia Pharmaceuticals’s P/E ratio?
About 6.9, based on the last twelve months of diluted earnings per share (forward P/E about 16.0).
Is Aurinia Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 6% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Aurinia Pharmaceuticals pay a dividend?
Not currently.
Is Aurinia Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Aurinia Pharmaceuticals scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.